Quarterly report · Q1

Period2022-07-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥5.4bn2022-07-01 → 2022-09-30Cons.Net sales
Revenue¥20.4bn2021-07-01 → 2022-06-30Cons.Net sales (5-year summary)
Revenue¥4.8bn2021-07-01 → 2021-09-30Cons.Net sales
Operating income¥1.0bn2022-07-01 → 2022-09-30Cons.Operating income
Operating income¥871m2021-07-01 → 2021-09-30Cons.Operating income
Ordinary income¥979m2022-07-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥3.8bn2021-07-01 → 2022-06-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥876m2021-07-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥979m2022-07-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥876m2021-07-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥606m2022-07-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.4bn2021-07-01 → 2022-06-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥606m2021-07-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥606m2022-07-01 → 2022-09-30Cons.Profit loss
Net income¥606m2021-07-01 → 2021-09-30Cons.Profit loss
Total assets¥26.3bnat 2022-09-30Cons.Assets
Total assets¥26.2bnat 2022-06-30Cons.Assets
Total assets¥24.6bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥7.4bnat 2022-09-30Cons.Liabilities
Total liabilities¥7.6bnat 2022-06-30Cons.Liabilities
Net assets / equity¥18.8bnat 2022-09-30Cons.Net assets
Net assets / equity¥18.7bnat 2022-06-30Cons.Net assets
Net assets / equity¥16.9bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥8.6bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥9.1bnat 2022-06-30Cons.Cash and deposits
EPS (basic)¥15.292022-07-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥59.552021-07-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥15.292021-07-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio71.8%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio71.1%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio68.8%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-09-30−¥501m
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-09-30−¥501m
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-09-30¥6m
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentrevenue2022-07-01 → 2022-09-30¥4.0bn
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentrevenue external2022-07-01 → 2022-09-30¥3.5bn
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥501m
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentsegment profit2022-07-01 → 2022-09-30¥672m
jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue2022-07-01 → 2022-09-30¥1.9bn
jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue external2022-07-01 → 2022-09-30¥1.9bn
jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segmentsegment profit2022-07-01 → 2022-09-30¥337m
—segment totalrevenue2022-07-01 → 2022-09-30¥5.9bn
—segment totalrevenue external2022-07-01 → 2022-09-30¥5.4bn
—segment totalrevenue intersegment2022-07-01 → 2022-09-30¥501m
—segment totalsegment profit2022-07-01 → 2022-09-30¥1.0bn
Reconciling Itemsreconcilingrevenue2021-07-01 → 2021-09-30−¥498m
Reconciling Itemsreconcilingrevenue intersegment2021-07-01 → 2021-09-30−¥498m
Reconciling Itemsreconcilingsegment profit2021-07-01 → 2021-09-30−¥803,000
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentrevenue2021-07-01 → 2021-09-30¥3.6bn
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentrevenue external2021-07-01 → 2021-09-30¥3.1bn
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥498m
jpcrp040300-q1r_E34071-000Drug Substance Sales Businessreportable segmentsegment profit2021-07-01 → 2021-09-30¥609m
jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue2021-07-01 → 2021-09-30¥1.7bn
jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue external2021-07-01 → 2021-09-30¥1.7bn
jpcrp040300-q1r_E34071-000Pharmaceutical Marketing Businessreportable segmentsegment profit2021-07-01 → 2021-09-30¥262m
—segment totalrevenue2021-07-01 → 2021-09-30¥5.3bn
—segment totalrevenue external2021-07-01 → 2021-09-30¥4.8bn
—segment totalrevenue intersegment2021-07-01 → 2021-09-30¥498m
—segment totalsegment profit2021-07-01 → 2021-09-30¥871m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 353
ItemContextValueUnit
Deferred tax assetsPrior1YearInstant138633000JPY
Deferred tax assetsCurrentQuarterInstant115127000JPY
Net defined benefit assetPrior1YearInstant34262000JPY
Net defined benefit assetCurrentQuarterInstant34350000JPY
Other ioaPrior1YearInstant11602000JPY
Other ioaCurrentQuarterInstant17191000JPY
Investments and other assetsPrior1YearInstant248229000JPY
Investments and other assetsCurrentQuarterInstant232176000JPY
Noncurrent assetsPrior1YearInstant6844113000JPY
Noncurrent assetsCurrentQuarterInstant6687787000JPY
AssetsPrior1YearInstant26249934000JPY
AssetsCurrentQuarterInstant26250193000JPY
Notes and accounts payable tradePrior1YearInstant1464164000JPY
Notes and accounts payable tradeCurrentQuarterInstant1893825000JPY
Electronically recorded obligations operating clPrior1YearInstant658864000JPY
Electronically recorded obligations operating clCurrentQuarterInstant628572000JPY
Short term loans payablePrior1YearInstant850000000JPY
Short term loans payableCurrentQuarterInstant850000000JPY
Current portion of long term loans payablePrior1YearInstant349904000JPY
Current portion of long term loans payableCurrentQuarterInstant349904000JPY
Income taxes payablePrior1YearInstant809405000JPY
Income taxes payableCurrentQuarterInstant360376000JPY
Provision for bonusesPrior1YearInstant48224000JPY
Provision for bonusesCurrentQuarterInstant113894000JPY
Other clPrior1YearInstant757440000JPY
Other clCurrentQuarterInstant651602000JPY
Current liabilitiesPrior1YearInstant4938004000JPY
Current liabilitiesCurrentQuarterInstant4848175000JPY
Long term loans payablePrior1YearInstant2291192000JPY
Long term loans payableCurrentQuarterInstant2219192000JPY
Deferred tax liabilitiesPrior1YearInstant6311000JPY
Deferred tax liabilitiesCurrentQuarterInstant2865000JPY
Provision for directors retirement benefitsPrior1YearInstant124588000JPY
Provision for directors retirement benefitsCurrentQuarterInstant127400000JPY
Net defined benefit liabilityPrior1YearInstant120339000JPY
Net defined benefit liabilityCurrentQuarterInstant120763000JPY
Other nclPrior1YearInstant103666000JPY
Other nclCurrentQuarterInstant96913000JPY
Noncurrent liabilitiesPrior1YearInstant2646098000JPY
Noncurrent liabilitiesCurrentQuarterInstant2567134000JPY
LiabilitiesPrior1YearInstant7584102000JPY
LiabilitiesCurrentQuarterInstant7415309000JPY
Capital stockPrior1YearInstant522277000JPY
Capital stockCurrentQuarterInstant522277000JPY
Capital surplusPrior1YearInstant205828000JPY
Capital surplusCurrentQuarterInstant205828000JPY
Retained earningsPrior1YearInstant17920673000JPY
Retained earningsCurrentQuarterInstant18090769000JPY
Treasury stockPrior1YearInstant-407000JPY
Treasury stockCurrentQuarterInstant-407000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-06-30pass
balance sheet identityconsolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-06-30pass
statement vs summary · total assetsconsolidated 2022-09-30pass